Journal
CHIRALITY
Volume 30, Issue 6, Pages 769-776Publisher
WILEY
DOI: 10.1002/chir.22847
Keywords
ethyl (R)-3-hydroxybutyrate; kinetic resolution; novel esterase; opposite enantio-selectivity; process optimization
Funding
- Strategic Priority Research Program of the Chinese Academy of Sciences [XDA11030404]
- Scientific and Technological Project of Ocean and Fishery from Guangdong Province [A201701C12]
- Guangzhou Science and Technology Plan Projects [201510010012]
Ask authors/readers for more resources
The two enantiomers of ethyl 3-hydroxybutyrate are important intermediates for the synthesis of a great variety of valuable chiral drugs. The preparation of chiral drug intermediates through kinetic resolution reactions catalyzed by esterases/lipases has been demonstrated to be an efficient and environmentally friendly method. We previously functionally characterized microbial esterase PHE21 and used PHE21 as a biocatalyst to generate optically pure ethyl (S)-3-hydroxybutyrate. Herein, we also functionally characterized one novel salt-tolerant microbial esterase WDEst17 from the genome of Dactylosporangium aurantiacum subsp. Hamdenensis NRRL 18085. Esterase WDEst17 was further developed as an efficient biocatalyst to generate (R)-3-hydroxybutyrate, an important chiral drug intermediate, with the enantiomeric excess being 99% and the conversion rate being 65.05%, respectively, after process optimization. Notably, the enantio-selectivity of esterase WDEst17 was opposite than that of esterase PHE21. The identification of esterases WDEst17 and PHE21 through genome mining of microorganisms provides useful biocatalysts for the preparation of valuable chiral drug intermediates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available